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Matrix metalloproteinase 2–induced venous
dilation via hyperpolarization and activation of
K channels: Relevance to varicose vein formation
Joseph D. Raffetto, MD,a Reagan L. Ross, BS, MPT,b and Raouf A. Khalil, MD, PhD,b,c
West Roxbury and Boston, Mass
Background: Varicose veins are a common disorder of extensive venous dilation and remodeling with an as-yet unclear
mechanism. Studies have shown increased plasma and tissue levels of matrix metalloproteinases (MMPs) in human
varicose veins and animal models of venous hypertension. Although the effects of MMPs are generally attributed to
extracellular matrix degradation, their effects on the mechanisms of venous contraction/relaxation are unclear. Our
preliminary experiments have demonstrated that MMP-2 causes inhibition of phenylephrine-induced venous contraction.
The purpose of this study was to determine whether MMP-induced inhibition of venous contraction involves an
endothelium-dependent and/or -independent pathway.
Methods: Circular segments of the inferior vena cava (IVC) were isolated from male Sprague-Dawley rats and suspended
between two wire hooks in a tissue bath, and the effects of MMP-2 on phenylephrine- and KCl-induced contraction were
measured. To study the role of endothelium-derived vasodilators, experiments were performed in the presence and absence of
endothelium; NG-L-nitro-arginine methyl ester (L-NAME), an inhibitor of nitric oxide synthesis; indomethacin, an inhibitor
of prostacyclin synthesis; cromakalim, an activator of adenosine triphosphate–sensitive K channels (KATP); and iberiotoxin,
a blocker of large-conductance Ca2-dependent K channels (BKCa) and smooth muscle hyperpolarization.
Results: In endothelium-intact IVC segments, phenylephrine (105 mol/L) caused significant contraction that slowly
declined to 82.0% in 30 minutes. The addition of MMP-2 (1g/mL) caused a gradual decrease of phenylephrine contraction
to 39.5% at 30 minutes. In endothelium-denuded IVC, MMP-2 induced a greater reduction of phenylephrine contraction, to
7.6%. In the presence of L-NAME (104 mol/L), MMP-2 caused a marked decrease in phenylephrine contraction, to 4.4%.
Large MMP-2–induced inhibition of phenylephrine contraction was also observed in IVC treated with L-NAME plus
indomethacin. MMP-2 caused relaxation of phenylephrine contraction in IVC pretreated with cromakalim (107 mol/L),
an activator of KATP channels. MMP-2–induced inhibition of phenylephrine contraction was abrogated in the presence of
iberiotoxin (108 mol/L), a blocker of BKCa. MMP-2 did not inhibit venous contraction during membrane depolariza-
tion by 96 mmol/L KCl, a condition that prevents outward K conductance and cell hyperpolarization.
Conclusions: MMP-2 causes significant IVC relaxation that is potentiated in the absence of endothelium or during
blockade of endothelium-mediated nitric oxide and prostacyclin synthesis. The lack of effects of MMP-2 on KCl
contraction and in iberiotoxin-treated veins suggests MMP-2–induced smooth muscle hyperpolarization and activation
of BKCa channels—a novel effect of MMP that may play a role in the early stages of venous dilation and varicose vein
formation. (J Vasc Surg 2007;45:373-80.)
Clinical Relevance:The pathogenesis of varicose vein formation is unclear. Studies in humans suggest a possible role of MMPs
in varicose vein formation and venous insufficiency. Also, studies in animal models of venous hypertension have demonstrated
increased MMP levels in vein tissue and valve remodeling. However, there is no evidence of a causal relationship between
venous MMP levels and varicose veins. Also, the implication of MMPs is based on an observed increase in their expression
antecedent to or in association with the venous dilation, valve dysfunction, and tortuosity seen during varicose vein formation.
Furthermore, a mechanistic model to study the role of MMPs in varicose vein formation is lacking. In this study, we
demonstrate that MMP-2 causes relaxation of phenylephrine-contracted IVC segments by a mechanism involving hyperpo-
larization and likely activation of BK . In chronic conditions of venous hypertension, protracted MMP-2–induced venousCa
relaxation could lead to progressive venous dilation, varicose vein formation, and chronic venous insufficiency.Varicose veins are a common disorder, with an esti-
mated prevalence of 5% to 30% of the adult population.1
More than 50% of women and 20% of men with varicose
veins will have chronic venous insufficiency with clinical
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nous insufficiency can lead to venous ulceration, affecting
up to 2.5 million people each year.3 Although the risk
factors for varicose veins—such as female sex, pregnancy,
obesity, aging, and family history—have been identified,2,4
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and progression of varicose veins remain unclear.
Matrix metalloproteinases (MMPs) are a family of zinc-
containing proteolytic enzymes that degrade and remodel
the extracellular matrix.5 MMPs play a key role in wound
healing, inflammation, and smooth muscle cell migration.5,6
MMPs also have a significant effect on vascular tissue remod-
eling that could play a role in the pathogenesis and progres-
sion of vascular disease. For example, MMPs have been
implicated in the pathogenesis of abdominal aortic aneu-
rysms by inducing destruction of the elastic lamellae and
extracellular matrix, arterial wall degradation and weaken-
ing, and progressive aortic dilation.7-9 MMPs may also be
involved in atherosclerotic plaque instability, and a role of
MMP-2 in atherosclerosis and plaque rupture has been
demonstrated during arterial lesion progression.10,11
Previous studies have shown that the plasma and ve-
nous tissue levels of MMP-1, -2, -3, -9, and -13 are in-
creased in human varicose veins, thus suggesting that
MMPs may contribute to the pathogenesis of the dis-
ease.12-15 MMPs have been detected in all histologic layers
of the venous wall, and increased MMP expression and
activity have been demonstrated in thrombophlebitic vari-
cose veins.14 However, the presence of MMPs in varicose
veins could be merely a component of the chronic inflam-
matory process. Also, increased MMP activity in the ad-
vanced thrombophlebitic stages does not address whether
MMPs affect venous function at the early stages of varicose
vein formation.
We have previously shown that MMPs cause relaxation
of the rat aorta and suggested a role of MMPs in the aortic
dilation associated with aneurysm formation.16 Also, our
preliminary experiments suggest that MMP-2 causes relax-
ation of phenylephrine contraction in rat inferior vena cava
(IVC).17 The purpose of this study was to test whether
MMP-2–induced venous relaxation involves an endothelium-
dependent mechanism or an endothelium-independent in-
hibition of venous smooth muscle contraction. To test this
novel hypothesis, we evaluated the effects of MMP-2 in rat
IVC in the presence and absence of endothelium, in the
presence and absence of inhibitors of endothelium-derived
vasodilators, and during modulation of K channel activity
by depolarizing solutions and by activators and blockers of
K channels.
MATERIALS AND METHODS
Solutions and drugs. Krebs solution contained the
following (mmol/L): NaCl 120, KCl 5.9, NaHCO3 25,
NaH2PO4 1.2, dextrose 11.5, CaCl2 2.5, and MgCl2 1.2
(pH 7.4), bubbled with 95% oxygen and 5% carbon diox-
ide. A total of 96 mol/L KCl was prepared as Krebs
solution with equimolar substitution of NaCl with KCl.
Tested drugs included phenylephrine, acetylcholine, NG-
L-nitro-arginine methyl ester (L-NAME), indomethacin
(Sigma, St Louis, Mo), MMP-2 (recombinant human,
active form; Biomol, Plymouth Meeting, Pa), cromakalim
(activator of adenosine triphosphate–sensitive K channels
[KATP]; Sigma), and iberiotoxin (blocker of BKCa; Calbio-chem, La Jolla, Calif). All other chemicals were of reagent
grade or better.
Animals and tissues. Male Sprague-Dawley rats (12
weeks, 250-300 g; Charles River Laboratories, Wilming-
ton, Mass) were killed by inhalation of carbon dioxide. The
abdominal cavity was opened, and the IVC was rapidly
excised, placed in oxygenated Krebs solution, and carefully
dissected and cleaned of connective tissue under micro-
scopic visualization. The IVC was portioned into 3-mm
rings in preparation for isometric contraction experiments.
All procedures followed the guidelines of the Institutional
Animal Care and Use Committee.
Isometric contraction. IVC segments were sus-
pended between two wire hooks. One hook was fixed, and
the other hook was connected to a Grass force transducer
(FT03) (Astro-Med, Inc, West Warwick, RI). Vein seg-
ments were stretched under 0.5 g of resting tension and
allowed to equilibrate for 45 minutes in a temperature-
controlled, water-jacketed tissue bath filled with 50 mL of
Krebs solution continuously bubbled with 95% oxygen and
5% carbon dioxide at 37°C. The changes in isometric
contraction were recorded on a Grass polygraph (model
7D; Astro-Med, Inc, West Warwick, RI).
Two control 96 mmol/L KCl contractions, each fol-
lowed by three washings in Krebs solution, were first per-
formed. A contraction to phenylephrine 105 mol/L was
then elicited. When phenylephrine-induced contraction
reached steady state, MMP-2 was added, and its effect was
observed. We have previously performed dose-response and
time-course experiments with MMPs in rat aorta rings.16
We found that MMP-2 at a 1 g/mL concentration caused
maximum aortic relaxation in 30 minutes. Also, our pre-
liminary data on the IVC have shown time-dependent
MMP-2–induced relaxation that reached steady state in
30 minutes.17 Therefore, in all experiments, 1 g/mL
MMP-2 was used, and its effects were measured after 30
minutes. To inhibit nitric oxide (NO) synthesis or cyclo-
oxygenases, the tissues were treated for 10 minutes with
L-NAME (104 mol/L) or indomethacin (105 mol/L),
respectively. The role of K channels was tested by measur-
ing the effects of MMP-2 on phenylephrine contraction in
the presence of the KATP activator cromakalim (10
7
mol/L) and the BKCa blocker iberiotoxin (10
8 mol/L).
Acetylcholine (105 mol/L) relaxation of the phenyleph-
rine contraction was performed to confirm the presence of
intact endothelium. In some experiments, the endothelium
was mechanically removed by gently scraping the intimal
surface of the IVC segment around the tip of forceps, and
removal of the endothelium was confirmed by the absence
of acetylcholine relaxation.
Nitrite/nitrate measurements. Endothelium-intact
IVC segments were placed in 1.5 mL of Krebs solution
aerated with 95% oxygen and 5% carbon dioxide at 37°C,
and the solution was changed every 30 minutes for 1 hour.
Samples for basal accumulation of nitrite (NO2
) formed
from released NO were taken. IVC segments were treated
with acetylcholine or MMP-2 for 30 minutes and then rapidly
removed, dabbed dry with filter paper, and weighed. The
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uct of NO, NO2
. Briefly, samples of incubation solution
(50 L, in triplicate) were mixed in a 96-well microplate
with 100 L of Griess reagent. The chromophore gener-
ated from the reaction with NO2
 was detected spectro-
photometrically (535 nm) by using a SpectraMAX micro-
plate reader (Molecular Devices, Sunnyvale, Calif). The
concentration of NO2
 was calculated by using a calibra-
tion curve with known concentrations of NaNO2.
NO production. NO measurements were confirmed
with 4-amino-5-methylamino-2=,7=-difluorescein (DAF-
FM), an NO-sensitive fluorescent dye.18 IVC rings were
placed in test tubes containing 2 mL Krebs and 7 mol/L
DAF for 45 minutes. Samples for basal accumulation of NO
were taken. The IVC rings were treated with acetylcholine
or MMP-2 for 30 minutes and then removed, dabbed dry
with filter paper, and weighed. The fluorescence of the
incubation solutions was measured (50 L, in triplicate) in
a 96-well microplate by using a SpectraMAX microplate
reader with an excitation wavelength of 495 nm and an
emission wavelength of 520 nm.
Statistical analysis. Data are presented as mean 
SEM. Data were analyzed by using analysis of variance
followed by the Scheffé F test for comparison of multiple
Fig 1. Matrix metalloproteinase (MMP)-2–induced rel
intact inferior vena cava (IVC) segments not treated
(L-NAME; 104 mol/L) (B) or L-NAME plus indom
segments (D). When Phe (105 mol/L) reached a stead
contraction was observed. The traces are representative
segments.means. The Student t test for unpaired and paired data wasused for comparison of two means. Differences were con-
sidered statistically significant if P  .05.
RESULTS
MMP-2 induces relaxation of phenylephrine contrac-
tion. In endothelium-intact IVC, phenylephrine caused
significant contraction that ranged between 0.5 and 0.6 g.
Phenylephrine contraction showed a gradual decline with
time and reached 82.0%  2.4% of the initial control
contraction in 30 minutes. MMP-2 (1 g/mL) caused
relaxation of the phenylephrine contraction to between 0.2
and 0.3 g, or 39.5% 10.5% of the control contraction, in
30 minutes (n 5; P  .029; Fig 1). To determine whether
MMP-2 acts via an endothelium-dependent mechanism,
the effects of MMP-2 were compared in endothelium-
denuded and intact IVC. Removal of the endothelium did
not inhibit MMP-2–induced relaxation. Instead, MMP-2
caused greater inhibition of phenylephrine contraction to
7.6%  2.0% in endothelium-denuded (n  4; P  .032)
compared with intact IVC (Fig 1).
Effects of L-NAME on MMP-2–induced IVC
relaxation. To determine whether MMP-2–induced IVC
relaxation involves the NO pathway, NO synthesis was
blocked by the NO synthase (NOS) inhibitor L-NAME
n of phenylephrine (Phe) contraction in endothelium-
or pretreated with NG-L-nitro-arginine methyl ester
cin (105 mol/L) (C) or endothelium-denuded IVC
e, MMP-2 (1 g/mL) was added, and its effect on Phe




of th(104 mol/L). In L-NAME–pretreated IVC, MMP-2 still
JOURNAL OF VASCULAR SURGERY
February 2007376 Raffetto, Ross, and Khalilcaused significant relaxation of the phenylephrine contrac-
tion to 4.4%  1.6% of control (n  3; P  .028). The
MMP-2–induced relaxation of the phenylephrine contrac-
tion was significantly greater in the presence of L-NAME
compared with that in the absence of L-NAME (P  .046;
Figs 1 and 2).
Effect of MMP-2 on NO production. NO was
assayed in IVC at basal levels and in the presence of MMP-2
(1 g/mL) or acetylcholine (105 mol/L). Acetylcholine
caused a significant increase in NO production above basal
levels. MMP-2 did not significantly increase NO produc-
tion and seemed to cause a reduction in NO production
compared with basal levels (n  3; Fig 3).
Effect of indomethacin on MMP-2–induced IVC
relaxation. To determine whether MMP-2–induced IVC
relaxation involves a prostacyclin (PGI2)-dependent relax-
ation pathway, the effects of indomethacin, an inhibitor of
cyclo-oxygenases, were tested. In IVC pretreated with in-
domethacin (105 mol/L), MMP-2 caused relaxation of
the phenylephrine contraction to 49.8% 3.5% of control,
which was not different from that in tissues treated with
MMP-2 alone (P  .43). In IVC pretreated with indo-
methacin plus L-NAME, MMP-2 caused a significant relax-
ation of the phenylephrine contraction to 6.5%  1.2% of
control (P  .0001; Figs 1 and 2).
Effect of 96 mmol/L KCl on MMP-2–induced IVC
relaxation. To determine whether MMP-2–induced IVC
relaxation involves hyperpolarization of vascular cells, we
measured the effect of MMP-2 in the presence of high-KCl
depolarizing solution. MMP-2 did not cause any significant
relaxation of KCl contraction (95.3%  2.8%; Fig 4). In
contrast, the addition of acetylcholine caused significant
relaxation of the KCl contraction.
Effect of cromakalim (a KATP activator). To test
Fig 2. Aggregate data evaluating the effect of matrix metallo-
proteinase (MMP)-2 on phenylephrine (Phe) contraction in
endothelium-intact inferior vena cava (IVC) segments not treated
or treated with NG-L-nitro-arginine methyl ester (L-NAME) and
indomethacin and in endothelium-denuded segments (-endo).
Data represent the mean  SEM of measurements in three to five
experiments. *P  .05 compared with control experiments in
endothelium-intact tissues and experiments in endothelium-
blocked tissues.whether MMP-2–induced relaxation involves hyperpolar-ization and activation of KATP channels, we examined
whether prior activation of KATP with cromakalim would
prevent MMP-2–induced IVC relaxation. The addition of
cromakalim (107 mol/L) caused significant relaxation of
the phenylephrine contraction. The addition of MMP-2
caused further relaxation of the IVC to baseline, thus
indicating that MMP-2–induced hyperpolarization and re-
laxation involve mechanisms other than the KATP channel
(Fig 5).
Effect of iberiotoxin (a blocker of BKCa). To fur-
ther evaluate the role of K channels in MMP-2–induced
IVC relaxation, the effect of blocking BKCa was tested. The
addition of iberiotoxin (108 mol/L) to MMP-2–treated
IVC caused significant attenuation of relaxation (12.1% 
3.6%) compared with the control MMP-2–induced relax-
ation (60.5%  10.5%; P  .0058; n  5; Fig 6).
DISCUSSION
This study demonstrated that MMP-2 induces signifi-
cant relaxation of IVC segments precontracted with phen-
ylephrine. Although the effects of MMPs on the vascular
extracellular matrix are well documented, little is known
regarding the effects of MMPs on the endothelium and
smooth muscle. Immunohistochemical studies have shown
that MMPs are localized not only in the vein adventitia
and extracellular matrix, but also in the endothelium and
Fig 3. Effect of matrix metalloproteinase (MMP)-2 on nitrite/
nitrate production as measured by Griess reagent (A) and on nitric
oxide (NO) production as measured by 4-amino-5-methylamino-
2=,7=-difluorescein (DAF) fluorescence (B). Basal, MMP-2, and
acetylcholine (ACh)-induced NO production were measured. Data
represent the mean SEM of measurements in three experiments.smooth muscle cells.14 The observed relatively rapid
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vation of an endothelium-dependent relaxation pathway,
endothelium-independent inhibition of venous smooth
muscle contraction, or both.
The enhanced MMP-induced relaxation in endothelium-
denuded compared with intact veins suggests that an
endothelium-derived contracting or relaxation factor (or
factors) may interfere with MMP-2–induced vasodila-
tion. Minimizing these endothelial factors (by mechani-
cal removal of the endothelium or chemical blocking of
endothelium-derived mediators) would lead to enhanced
MMP-2 vasodilation. Studies have suggested that MMP-2
could cleave big endothelin 1, thus yielding a novel vaso-
constrictor and thereby enhancing vascular contraction, an
effect that will not be manifested in endothelium-denuded
tissues.19 MMP-2–induced venous relaxation could also be
due to enhanced release of NO, PGI2, or endothelium-
derived hyperpolarizing factor (EDHF).20
Studies have suggested a role of MMPs in blood flow–
induced arterial dilation via interaction with NO, thus
raising the possibility that MMPs may be coupled to endo-
thelial NOS stimulation and activation of the NO/cyclic
guanosine monophosphate venous relaxation pathway.21
We found that the NOS inhibitor L-NAME did not atten-
Fig 4. Effects of matrix metalloproteinase (MMP)-2 during
membrane depolarization by KCl, a condition that does not favor
K efflux and cell hyperpolarization. High KCl (96 mmol/L)
contraction was elicited, MMP-2 (1 g/mL) was added, and its
lack of effect was observed. Data represent the mean  SEM.uate and, instead, enhanced MMP-2–induced IVC relax-ation. Also, MMP-2 did not increase NO production, as
measured by Griess reagent and DAF fluorescence. Al-
though the data suggest that MMP-2–induced venous
relaxation may not involve increased NO production, they
do not rule out a possible interaction between the NO
pathway and MMP. NO, being a major vasodilator, may
downregulate the effects of MMP-2 on other endothelium-
derived vasodilators, and NOS inhibition may unmask
these effects. Also, studies have shown that NO inhibition
may increase MMP-9 expression in rat vascular smooth
muscle cells.22 MMP-2 may also directly, or indirectly
through increased endothelin 1 production, induce NOS
uncoupling and lead to increased superoxide production
and decreased NO bioactivity.23,24 We have also found that
the MMP-2–induced venous relaxation was not affected by
the cyclo-oxygenase inhibitor indomethacin, thus suggest-
ing that it does not involve increased PGI2 synthesis and
activation of PGI2/cyclic adenosine monophosphate relax-
ation pathway.
The inability of NOS and cyclo-oxygenase inhibition to
block the MMP-2–induced venous relaxation raises the
possibility of MMP-2–mediated release of EDHF leading
to enhanced K efflux via K channels and venous smooth
muscle hyperpolarization and relaxation. To test the possi-
ble role of EDHF, we examined whether MMP-2–induced
venous relaxation is affected by changing the extracellular
K concentration gradient or by K channel modulators.
Fig 5. Effect of cromakalim on matrix metalloproteinase (MMP)-
2–induced inferior vena cava (IVC) relaxation. IVC contraction to
phenylephrine (Phe) was elicited. Control tissue (upper panel) was
treated with vehicle Krebs solution. In other tissues (lower panel),
cromakalim (107 mol/L) was added, and IVC relaxation was
observed. MMP-2 was then added, and further IVC relaxation to
baseline could be observed.High extracellular KCl creates a K concentration gradient
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K channels. In this study, MMP-2 did not inhibit venous
contraction during membrane depolarization by high KCl,
thus suggesting that MMP-2–induced relaxation likely in-
volves hyperpolarization and activation of a K channel.
K channels include the KATP channel, BKCa channel,
intermediate- and small-conductance Ca2-activated K
channels, voltage-gated K channels, and inward rectifier
K channels.25 In human saphenous vein, the K channel
opener cromakalim works mainly by activating the KATP
channel.26,27 If MMP-2 causes venous relaxation by acti-
vating the KATP channel, one would predict that after the
addition of cromakalim, MMP-2 should not cause any
further IVC relaxation. MMP-2 caused further IVC relax-
ation in cromakalim-treated IVC, thus suggesting that
MMP-2–induced venous relaxation involves K channels
Fig 6. Effect of iberiotoxin on matrix metalloproteinase (MMP)-
2–induced inferior vena cava (IVC) relaxation. IVC contraction to
phenylephrine (Phe) was elicited. Control tissue (top panel) was
treated with vehicle Krebs solution. In other tissues (middle
panel), the addition of iberiotoxin (a BKCa blocker) prevented
MMP-2–induced relaxation of Phe-contracted IVC. The cumula-
tive effects of MMP-2 in the absence or presence of iberiotoxin are
presented in the bottom panel. *P  .05.other than the KATP channel.To test whether MMP-2–induced venous relaxation
involves activation of BKCa, we examined whether the
effects of MMP-2 are reversed by iberiotoxin, a specific
blocker of BKCa.
25 Iberiotoxin at 108 mol/L, which is
10-fold lower than its median inhibitory concentration
(107 mol/L), essentially abolished MMP-2–induced IVC
relaxation; this supports that MMP-2–induced IVC dila-
tion is, in part, mediated through hyperpolarization and
activation of BKCa. However, the data do not exclude
possible involvement of other types of K channels in IVC
relaxation.
The question arises as to how MMP-2–induced acti-
vation of K channels could cause venous relaxation. Acti-
vation of K channels likely causes smooth muscle hyper-
polarization and leads to decreased Ca2 influx through
voltage-gated channels. This is supported by a previous
study that demonstrated that MMP-2 and MMP-9 cause
aortic dilatation by inhibiting Ca2 entry into aortic smooth
muscle.16 Another question is how MMP-2 causes activa-
tion of K channels. Although MMP-2 does not seem to
increase endothelium-derived NO or PGI2, it could still
interact with the endothelium and induce the release of
EDHF. MMPs have been shown to promote bradykinin
release in the vein wall, and this could in turn increase the
release of endothelium-derived relaxing factors.28-30 Al-
though the exact nature of EDHF is unclear, studies sug-
gest that EDHF-mediated responses could involve ep-
oxyeicosatrienoic acids, which are epoxides of arachidonic
acid generated by cytochrome P450 epoxygenases.31 Other
possible EDHFs include hydrogen peroxide.32 Whether
inhibition of cytochrome P450 epoxygenases or hydrogen
peroxide production prevents MMP-induced dilation
would determine the importance of these EDHFs in the
MMP-mediated effects.
MMP-2 could also directly activate the K channels.
MMP may facilitate a conformational change in the BKCa
channel from a closed state to an open state during changes
in voltage and intracellular Ca2.33,34 Other possibilities
include increases in the Arg-Gly-Asp (RGD) tripeptide–
containing sequence as a result of collagen degradation
by the protease activity of MMP-2. Soluble RGD peptide
can then bind to smooth muscle v3 integrin receptors
and lead to activation of K channels, venous hyperpo-
larization, and relaxation.35,36 This is supported by re-
ports that RGD peptide-integrin signaling and vasodila-
tion may involve modulation of the voltage-gated and
inward-rectifying K channels.36 MMP-2 may also acti-
vate K channels through specific protease-activated recep-
tors (PARs). PARs are activated by serine proteases such
as thrombin, trypsin, and tryptase.37,38 Trypsin causes an
L-NAME/indomethacin–resistant relaxation in mesenteric
arteries of PAR2/, but not PAR2/, mice.39 The
trypsin-induced PAR2-mediated relaxation was inhibited
by KCl precontraction or pretreatment with apamin or
charybdotoxin, blockers of small and intermediate Ca2-
activated K channels, respectively. These data suggest that
PAR2-mediated relaxation of the mouse vasculature in-
volves hyperpolarization of vascular smooth muscle and
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studies have shown that tissue inhibitor of metalloprotein-
ases 1 prevented MMP-2–induced relaxation of phenyleph-
rine contraction in the rat, possibly as a result of inhibition
of MMP-2 proteinase activity or tissue inhibitor of metal-
loproteinases 1 binding to integrins.40 Whether MMP-2–
induced venous relaxation and activation of K channels
involve RGD peptide-integrin signaling or PAR activation
remains to be investigated.
It would be of interest to study the direct effects of
MMP-2 on membrane potential and ion channel activities
in isolated vascular smooth muscle cells. MMPs regulate
the extracellular matrix turnover. Isolated vascular smooth
muscle cells lack a native extracellular matrix. An effect of
MMPs through integrins (which are components of the
extracellular matrix) would be minimized in the isolated
vascular smooth muscle cell system. Also, isolating vascular
cells often requires treating the blood vessels with collage-
nase/elastase. We have previously shown that elastase
causes vascular smooth muscle relaxation, which could
mask the effects of MMPs.41 Future studies would examine
experimental protocols to isolate vascular smooth muscle
cells by using small concentrations of proteases so that the
effects of MMPs are not compromised.
This study focused on testing the effects of MMP-2 on
venous function. Large amounts of MMP-2 have been
detected in the plasma and venous tissues of patients with
varicose veins. However, MMP-1, -3, -9, and -13 are also
expressed in human varicose veins.13-15 Also, it is possible
that some of the effects of MMP-2 could be due to activa-
tion of other endogenous MMPs.5 Future studies should
examine whether the effects of MMPs on the mechanisms
of venous relaxation are unique to MMP-2 or are caused by
other MMPs. Also, whether the observed effects of MMP
on IVC could also be demonstrated in other venous tissues,
such as the rat femoral vein and human saphenous vein,
should be examined in future experiments.
In conclusion, MMP-2 causes relaxation of phenyleph-
rine contractions in IVC segments by a mechanism involv-
ing hyperpolarization and activation of BKCa. A protracted
MMP-2–induced venous relaxation could lead to progres-
sive venous dilatation, varicose vein formation, and chronic
venous insufficiency.
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